Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Biogen (BIIB) falls as earnings, revenue misses consensus
February 13, 2024 7:24 AM ESTBiogen (NASDAQ: BIIB) shares are down more than 5% premarket Tuesday after the company reported earnings for its latest quarter, missing the consensus profit and revenue estimate.
The biotechnology firm reported fourth-quarter earnings of $2.95 per share, $0.23 worse than the analyst estimate of $3.18.... More
